

Supplementary Information

Materials

Antibodies and Chemicals- Sodium bicarbonate (NaHCO_3), disodium hydrogen phosphate (Na_2HPO_4), potassium chloride (KCl), tri-sodium citrate ($\text{Na}_3\text{C}_6\text{H}_5\text{O}_7$), sodium chloride (NaCl), magnesium chloride hexahydrate ($\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$), potassium dihydrogen orthophosphate (KH_2PO_4) and glucose were from Merck (Kilsyth, Victoria). Acid-soluble collagen and ADP were from Chrono-log Co (Havertown, PA). Protease activated receptor-4 (PAR-4) agonist peptide (HAla-Tyr-Pro-Gly-Lys-Phe-NH₂ (AYPGKF-NH₂) was from GL Biochem Ltd. (Shanghai, China). Type I collagen-related peptide (CRP) was from Richard Farndale (Cambridge University, Cambridge, UK). Xylazine was from Ilium, Troy Laboratories Pty Ltd (Smithfield, NSW, Australia). Ketamine was from Pfizer, (Auckland, New Zealand). Protease activated receptor-1 (PAR-1, SFLLRN), HEPES, dimethyl sulfoxide (DMSO), prostaglandin E₁ (PGE₁), iron (III) Chloride (FeCl_3) bovine serum albumin (BSA), Rhodamine G6 dye (Rh6G), paraformaldehyde, acetylsalicylic acid (aspirin), thrombin, eptifibatide acetate, dynasore hydrate and quinacrine were from Sigma-Aldrich (St Louis, MO, USA). Type I collagen fibrils was from Nycomed (Linz, Austria). Human vWF was from Jomar Life Research (Scoresby, Victoria). FITC anti human CD62P antibody was from BD Biosciences Pharmingen (Franklin Lakes, NJ, USA). Phycoerythrin (PE)-conjugated anti-human CD42b (GPIb α) was from Life Technologies Australia Pty Ltd (Mulgrave, Victoria). Anti-human GPVI PE and anti-human CD41 PE conjugated antibodies was from Becton Dickinson (North Ryde, NSW). GM6001 (a broad spectrum metalloproteinase inhibitor) was from Calbiochem (La Jolla, CA). TAPI-2 inhibitor, rhodamine 6G dye and GI2504023 inhibitor were from Sigma-Aldrich (St. Louis, MO).

TACE fluorogenic substrate was from Sapphire Bioscience (Redfern, NSW). μ -Slide VI^{0.1} was from DKSH Australia (Hallam, Victoria).